mTOR pathway - novel modulator of astrocyte activity

Folia Biologica (Poland)

Volumn 63, Issue 2, 2015, Pages 95-105

  Latacz, Anna ^a   Russell, John A ^b   Ocloń, Ewa ^a   Zubel Lojek, Joanna ^a   Pierzchala Koziec, Krystyna ^a  

^a UNIVERSITY OF AGRICULTURE IN KRAKOW   (Poland)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Astrocytes; Central nervous system; mTOR; Rapamycin

Indexed keywords

MAMMALIA;

TOR SERINE-THREONINE KINASES;

ANIMALS; ASTROCYTES; CENTRAL NERVOUS SYSTEM; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ASTROCYTES; CENTRAL NERVOUS SYSTEM; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84937061525     PISSN: 00155497     EISSN: 17349168     Source Type: Journal    
DOI: 10.3409/fb63_2.95     Document Type: Review

References (137)

1. ABBOTT N.J, RONNBACK L., HANSSON E. 2006. Astrocyteendothelial interactions at the blood-brain barrier. Nat. Rev. Neurosci. 7: 41-53.
2. ACOSTA-JAQUEZ H.A., KELLER J.A., FOSTER K.G., EKIM B., SOLIMAN G.A., FEENER E.P., BALLIF B.A., FINGAR D.C. 2009. Site-specific mTOR phosphorylation promotes mTORC1-mediated signaling and cell growth. Mol. Cell. Biol. 29: 4308-4324.
3. AKAOKA H., SZYMOCHA R., BEURTON-MARDUEL P., BER-NARD A., BELIN M.F., GIRAUDON P. 2001. Functional changes in astrocytes by human T-lymphotropic virus type-1 T-lymphocytes. Virus. Res. 78: 57-66.
4. AN W.L., COWBURN R.F., LI L., BRAAK H., ALAFUZOFF I., IQBAL K., IQBAL G., WIINBLAND B., PEI J.J. 2003. Upregulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease. Am. J. Pathol. 163: 591-607.
5. ANDREIUOLO F., JUNIER M.P., HOL E.M., MIQUEL C., CHI-MELLI L., LEONARD N., CHNEIWEISS H., DAUMAS-DUPORT C., VARLET P. 2009. GFAPdelta immunostaining improves visualization of normal and pathologic astrocytic heterogeneity. Neuropathology 29: 31-39.
6. ARCELLA A., BIAGIONI F., ANTONIETTA OLIVA M., BUCCI D., FRATI A., ESPOSITO V., CANTORE G., GIANGASPERO F., FORNAI F. 2013. Rapamycin inhibits the growth of glioblastoma. Brain. Res. 1495: 37-51.
7. AVRUCH J., LIN Y., LONG X., MURTHY S., ORTIZ-VEGA S. 2005. Recent advances in the regulation of theTORpathway by insulin and nutrients. Curr. Opin. Clin. Nutr. Metab. Care 8: 67-72.
8. BACKMAN S.A., STAMBOLIC V., SUZUKI A., HAIGHT J., ELIA A., PRETORIUS J., TSAO M.S., SHANNON P., BOLON B., IVY G.O., MAK T. W. 2001. Deletion of Pten in mouse brain causes seizures, ataxia and defects in soma size resembling Lhermitte-Duclos disease. Nat. Genet. 29: 396-403.
9. BALLABH P., BRAUN A., NEDERGAARD M. 2004. The bloodbrain barrier: an overview: structure, regulation, and clinical implications. Neurobiol. Dis. 16: 1-13.
10. BARRES B.A. 2008. The mystery and magic of glia: a perspective on their roles in health and disease. Neuron 60: 430-440.
11. BENJAMIN D., COLOMBI M., MORONI C., HALL M.N. 2011. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat. Rev. Drug. Discov. 10: 868-880.
12. BERGER Z., RAVIKUMAR B., MENZIES F.M., OROZ L.G., UNDERWOOD B.R., PANGALOS M.N., SCHMITT I., WULLNER U., EVERT B.O., O'KANE C.J., RUBINSZTEIN D.C. 2006. Rapamycin alleviates toxicity of different aggregateprone proteins. Hum. Mol. Genet. 15: 433-442.
13. BROWN E.J., ALBERS M.W., SHIN T.B., ICHIKAWA K., KEITH C.T., LANE W.S., SCHREIBER S.L. 1994. Amammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 369: 756-758.
14. BROWN A.M., RANSOM B.R. 2007. Astrocyte glycogen and brain energy metabolism. Glia 55: 1263-1271.
15. BUCHKOVICH N.J., YU Y., ZAMPIERI C.A., ALWINE J.C. 2008. The TORrid affairs of viruses: effects of mammalian DNA viruses on the PI3K-AKT-mTOR signaling pathway. Nat. Rev. Microbiol. 6: 266-275.
16. BUCKMASTER P.S., INGRAM E.A., WEN X. 2009. Inhibition of the mammalian target of rapamycin signaling pathway suppresses dentate granule cell axon sprouting in a rodent model of temporal lobe epilepsy. J. Neurosci. 29: 8259-8269.
17. BUSHONG E.A., MARTONE M.A., JONES Y.Z., ELLISMAN M.H. 2002.Protoplasmic astrocytes in CA1 atratum radiatum occupy separate anatomical domains. J. Neurosci. 22: 183-192.
18. BUTCHER R.A., BHULLAR B.S., PERLSTEIN E.O., MARSISSCHKY G., LABAER J., SCHREIBER S.L. 2006. Microarray-based method for monitoring yeast overexpression strains reveals small-molecule targets in TOR pathway. Nat. Chem. Biol. 2: 103-109.
19. BYFIELD M.P., MURRAY J.T., BACKER J.M. 2005. hVps34 is a nutrient-regulated lipid kinase required for activation of p70 S6 kinase. J. Biol. Chem. 280: 33076-33082.
20. CAMMALLERI M., LUTJENS R., BERTON F., KING A.R., SIMP-SON C., FRANCESCONI W., SANNA P.P. 2003. Timerestricted role for dendritic activation of the mTOR-p70S6K pathway in the induction of late-phase long-term potentiation in the CA1. Proc. Natl. Acad. Sci. USA. 100: 14368-14373.
21. CHASTRE A., JIANG W., DESJARDINS P., BUTTERWORTH R.F. 2010. Ammonia and proinflammatory cytokines modify expression of genes coding for astrocytic proteins implicated in brain edema in acute liver failure. Metab. Brain Dis. 25: 17-21.
22. CHEN L., WU J., WANG L., WANG J., QIN Z., DIFIGLIA M., LIN F. 2012. Rapamycin prevents the mutant huntingtin suppressed GLT-1 expression in cultured astrocytes. Acta Pharmacol. Sin. 33: 385-392.
23. CHING G.G., ABRAHAM R.T. 2005. Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. J. Biol. Chem. 280: 25485-25490.
24. CHOI K.C., KIM S.H., HA J.Y., KIM S.T., SON J.H. 2010. A novel mTOR activating protein protects dopamine neurons against oxidative stress by repressing autophagy related cell death. J. Neurochem. 112: 366-376.
25. CHONG Z.Z, SHANG Y.C., ZHANG L., WANG S., MAIESE K. 2010. Mammalian target of rapamycin: hitting the bull's-eye forneurologicaldisorders. Oxid. Med. CellLongev. 3:374-391.
26. CHONG Z.Z, SHANG Y.C., WANG S., MAIESE K. 2012. Shedding new light on neurodegenerative diseases through the mammalian target of rapamycin. Prog. Neurobiol. 99: 128-148.
27. CLABOUGH E.B. 2013. Huntington's disease: the past, present, and future search for disease modifiers. Yale J. Biol. Med. 86: 217-233.
28. CODELUPPI S., SVENSSON C.L., HEFFERAN M.P., VALENCIA F., SILLDORFF M.D., OSHIRO M., MARSALA M., PASQUALE E. B. 2009. The Rheb-mTOR pathway is upregulated in reactive astrocytes of the injured spinal cord. J. Neurosci. 29: 1093-1104.
29. COTA D., PROULX K., SMITH K.A., KOZMA S.C., THOMAS G., WOODS S.C., SEELEY R.J. 2006. Hypothalamic mTOR signaling regulates food intake. Science 312: 927-930.
30. COZZOLINO M., FERRI A., CARRÌ M.T. 2008. Amyotrophic lateral sclerosis: from current developments in the laboratory to clinical implications. Antioxid. Redox Signal. 10: 405-444.
31. CRACCO J.B., SERRANO P., MOSKOWITZ S.I., BERGOLD P.J., SACKTOR T.C. 2005. Protein synthesis-dependent LTP in isolated dendrites of CA1 pyramidal cells. Hippocampus 15: 551-556.
32. CULLY M., YOU H., LEVINE A.J., MAK T.W. 2006. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat. Rev. Cancer 6: 184-192.
33. CURATOLO P. 2003. Tuberous sclerosis complex: frombasic scienceto clinical phenotypes. MacKeithPress, London. Pp. 328.
34. CURATOLO P., BOMBARDIERI R., JOZWIAK S. 2008. Tuberous sclerosis. Lancet 372: 657-668.
35. CURATOLO P., MOAVERO R. 2012. mTOR inhibitors in tuberous sclerosis complex. Curr. Neuropharmacol. 10: 404-415.
36. CURRAN M.P. 2012. Everolimus: in patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex. Pediatr. Drugs 14: 51-60.
37. DELLO RUSSO C., LISI L., TRINGALI G., NAVARRA P. 2009. Involvement of mTOR kinase in cytokine-dependent microglial activation and cell proliferation. Biochem. Pharmacol. 78: 1242-1251.
38. DELLO RUSSO C., LISI L., FEINSTEIN D. L., NAVARRA P. 2013. mTOR kinase, a key player in the regulation of glial functions: relevance for the therapy of multiple sclerosis. Glia 61: 301-311.
39. DIGIORGIO F.P., CARRASCO M.A., SIAO M.C., MANIATIS T., EGGAN K. 2007. Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model. Nat. Neurosci. 10: 608-614.
40. DONG Y., BENVENISTE E.N. 2001. Immune function of astrocytes. Glia. 36: 180-190.
41. EEG-OLOFSSON O. 2003. Virological and immunological aspects of seizure disorders. Brain Dev. 25: 9-13.
42. ENG L.F., GHIRNIKAR R.S., LEE Y.L. 2000. Glial ?brillary acidic protein: GFAP-thirty-one years (1969-2000). Neurochem. Res. 25: 1439-1451.
43. ESTRADA-SÁNCHEZ A.M., REBEC G.V. 2012. Corticostriatal dysfunction and glutamate transporter 1 (GLT1) in Huntington's disease: interactions between neurons and astrocytes. Basal Ganglia 2: 57-66.
44. FAIDEAU M., KIM J., CORMIER K., GILMORE R., WELCH M., AUREGAN G., DUFOUR N., GUILLERMIER M., BROUILLET E., HANTRAYE P., DÉGLON N., FERRANTE R.J., BONVENTO G. 2010. In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington's disease subjects. Hum. Mol. Genet. 19: 3053-3057.
45. FAN Q.W., WEISS W.A. 2012. Inhibition of PI3K-Akt-mTOR signaling in glioblastoma by mTORC1/2 inhibitors. Methods Mol. Biol. 821: 349-359.
46. FAULKNER J.R., HERRMANN J.E., WOO M.J., TANSEY K.E., DOAN N.B., SOFRONIEW M.V. 2004. Reactive astrocytes protect tissue and preserve function after spinal cord injury. J. Neurosci. 24: 2143-2155.
47. FEINSTEIN D.L., GALEA E., CERMAK J., CHUGH P., LYAND-VERT L., REIS D.J. 1994. Nitric oxide synthase expression in glial cells: suppression by tyrosine kinase inhibitors. J. Neurochem. 62: 811-814.
48. FINGAR D.C., BLENIS J. 2004. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23: 3151-3171.
49. FURNARI F.B., FENTON T., BACHOO R.M., MUKASA A., STOMMEL J.M., ALEXANDER STEGH A., HAHN W.C., LIGON K.L., LOUIS D.N., BRENNAN C., CHIN L., DEPINHO R.A., CAVENEE W.K. 2007. Malignant astrocytic glioma:genetics, biology, and paths to treatment. Genes Dev. 21: 2683-2710.
50. GARCIA-SEGURA L.M., MCCARTHY M. 2004. Minireview:Role of glia in neuroendocrine function. Endocrinology 145: 1082-1086.
51. GETTS D.R., BALCAR V.J., MATSUMOTO I., MULLER M., KING N.J.C. 2008. Viruses and the immune system: their roles in seizure cascade development. J. Neurochem. 104: 1167-1176.
52. GINGRAS A.C., SCOTT G., KENNEDY S.G., O'LEARY M.A., SONENBERG N., HAY N. 1998. 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Genes Dev. 12: 502-513.
53. GRIFFIN R.J., MOLONEY A., KELLIHER M., JOHNSTON J.A., RAVID R., DOCKERY P., O'CONNOR R., O'NEILL C. 2005. Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology. J. Neurochem. 93: 105-117.
54. GU X., LI C., WEI W., LO V., GONG S., LI S., IWASATO T., ITOHARA S., LI X.J., MODY I., HEINTZ N., YANG X.W. 2005. Pathological cell-cell interactions elicited by a neuropathogenic form of mutant Huntingtin contribute to cortical pathogenesis in HD mice. Neuron 46: 433-444.
55. GU X., ANDRE V., CEPEDA C., LI S., LI X.J., LEVINE M., YANG X. W. 2007. Pathological cell-cell interactions are necessary for striatal pathogenesis in a conditional mouse model of Huntington's disease. Mol. Neurodegener. 2: 1-11.
56. GULHATI P., BOWEN K.A., LIU J., STEVENS P.D., RYCHAHOU P.G., CHEN M., LEE E.Y., WEISS H.L., O'CONNOR K.L., GAO T., EVERS B.M. 2011. mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer Res. 71: 3246-3256.
57. HALASSA M.M., FELLIN T., HAYDON P.G. 2007. The tripartite synapse: roles for gliotransmission in health and disease. Trends Mol. Med. 13: 54-63.
58. HALLETT L., FOSTER T., LIU Z., BLIEDEN M., VALENTIM J. 2011. Burden of disease and unmet needs in tuberous sclerosis complex with neurological manifestations: systematic review. Curr. Med. Res. Opin. 27: 1571-1583.
59. HAY N., SONENBERG N. 2004. Upstream and downstream of mTOR. Genes Dev. 18: 1926-1945.
60. HEITMAN J., MOVVA N. R., HALL M. N. 1991. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 253: 905-909.
61. HOLMES G.L., STAFSTROM C.E. 2007. Tuberous sclerosis complex and epilepsy: recent developments and future challenges. Epilepsia 48: 617-630.
62. HOU L., KLANN E. 2004. Activation of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin signaling pathway is required for metabotropic glutamate receptordependent long-termdepression. J. Neurosci. 24: 6352-6361.
63. HSIEH W. B., CHIU N.C., HU K.C., HO C.S., HUANG F.Y. 2007. Outcome of herpes simplex encephalitis in children. J. Microbiol. Immunol. Infect. 40: 34-38.
64. HUYNH D.P., VINTERS H.V., HO D.H., HO V.V., PULST S.M. 1997. Neuronal expression and intracellular localization of presenilins in normal and Alzheimer disease brains. J. Neuropathol. Exp. Neurol. 56: 1009-1017.
65. IMAI Y., GEHRKE S., WANG H-Q., TAKAHASHI R., HASE-GAWA K., OOTA E., LU B. 2008. Phosphorylation of 4E-BP byLRRK2affects the maintenance of dopaminergic neurons in Drosophila. EMBO J. 27: 2432-2443.
66. JOZWIAK J., KOTULSKA K., LOJEK M., GALUS R., JOZWIAK S., POLNIK D., WLODARSKI P.K. 2009. Fibroblasts from normal skin of a tuberous sclerosis patient show upregulation of mTOR pathway. Am. J. Dermatopathol. 31: 68-70.
67. KANDT R.S., HAINES J.L., SMITH M., NORTHRUP H., GARDNER R.J.M., SHORT M.P., DUMARS K., ROACH E.S., STEIN-GOLD S., WALL S., BLANTON S.H., FLODMAN P., KWIATKOWSKI D.J., JEWELL A., WEBER J.L., ROSES A.D., PERICAK-VANCE M.A. 1992. Linkage of an important gene locus for tuberous sclerosis to a chromosome 16 marker for polycystic kidney disease. Nat. Genet. 2: 37-41.
68. KATIYAR S., LIU E., KNUTZEN Ch. A., LANG E.S., LOMBARDO Ch. L., SANKAR S., TOTH J.I., PETROSKI M.D., RONAI Z., CHIANG G.G. 2009. REDD1, an inhibitor of mTOR signalling, is regulated by the CUL4A-DDB1 ubiquitin ligase. EMBO Reports 10: 866-872.
69. KELLEHER R.J. 3RD., GOVINDARAJAN A., TONEGAWA S. 2004. Translational regulatory mechanisms in persistent forms of synaptic plasticity. Neuron 44: 59-73.
70. KELLINGHAUS C., ENGBRING C., KOVAC S., MÖDDEL G., BOESEBECK F., FISCHERA M., ANNEKEN K., KLÖNNE K., REICHELT D., EVERS S., HUSSTEDT I.W. 2008. Frequency of seizures and epilepsy in neuro-logical HIV-infected patients. Seizure 17: 27-33.
71. KIRISCHUK S., PARPURA V., VERKHRATSKY A. 2012. Sodium dynamics: another key to astroglial excitability? Trends Neurosci. 35: 497-506.
72. KLEINERT H., PAUTZ A., LINKER K., SCHWARZ P.M. 2004. Regulation of the expression of inducible nitric oxide synthase. Eur. J. Pharmacol. 500: 255-266.
73. KOENIG M.K., BUTLER I.J., NORTHRUP H. 2008. Regression of subependymal giant cell astrocytoma with rapamycin in tuberous sclerosis complex. J. Child. Neurol. 23: 1238-1239.
74. KRUEGER D.A., CARE M.M, HOLLAND K.H., AGRICOLA K., TUDOR C., MANGESHKAR P., WILSON K.A., BYARS A., SAHMOUD T., FRANZ D.N. 2010. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N. Engl. J. Med. 363: 1801-1811.
75. KUCHIBHOTLA K.V., LATTARULO C.R., HYMAN B.T., BACSKAI B.J. 2009. Synchronous hyperactivity and intercellular calcium waves in astrocytes in Alzheimer mice. Science 323: 1211-1215.
76. KULIJEWICZ-NAWROT M., VERKHRATSKY A., CHVATAL A., SYKOVA E., RODRIGUEZ J.J. 2012. Astrocytic cytoskeletal atrophy in the medial prefrontal cortex of a triple transgenic mouse model of Alzheimer's disease. J. Anat. 221: 252-262.
77. LISI L., NAVARRA P., FEINSTEIN D.L., DELLO RUSSO C. 2011. The mTOR kinase inhibitor rapamycin decreases iNOS mRNAstability in astrocytes. J. Neuroinflammation 8: 1-11.
78. LJUNGBERG M.C., SUNNEN C.N., LUGO J.N., ANDERSON A.E., D'ARCANGELO G. 2009. Rapamycin suppresses seizures and neuronal hypertrophy in a mouse model of cortical dysplasia. Dis. Model Mech. 2: 389-398.
79. LOBSIGER C.S., CLEVELAND D.W. 2007. Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease. Nat. Neurosci. 10: 1355-1360.
80. MAIESE K., CHONG Z.Z, SHANG Y. Ch., WANG Sh. 2013. mTOR: on target for novel therapeutic strategies in the nervous system. Trends Mol. Med. 19: 51-60.
81. MALAGELADA C., RYU E.J., BISWAS S.C., JACKSON-LEWIS V., GREENE L.A. 2006. RTP801 is elevated in Parkinson brain substantia nigral neurons and mediates death in cellular models of Parkinson's disease by a mechanism involving mammalian target of rapamycin inactivation. J. Neurosci. 26: 9996-10005.
82. MANNING B.D., CANTLEY L.C. 2007. AKT/PKB signaling:navigating downstream. Cell 129: 1261-1274.
83. MATUTE C., MELONE M., VALLEJO-ILLARRAMENDI A., CONTI F. 2005. Increased expression of the astrocytic glutamate transporter GLT-1 in the prefrontal cortex of schizophrenics. Glia 49: 451-455.
84. MARTIN D.E., HALL M.N. 2005. The expanding TOR signaling network. Curr. Opin. Cell Biol. 17: 158-166.
85. MCGEER P.L, MCGEER E.G. 2008. Glial reactions in Parkinson's disease. Mov. Disord. 23: 474-483.
86. MEIKLE L., TALOS D.M., ONDA H., POLLIZZI K., ROTEN-BERG A., SAHIN M., JENSEN F.E., KWIATKOWSKI D.J. 2007. A mouse model of tuberous sclerosis: neuronal loss of Tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survival. J. Neurosci. 27: 5546-5558.
87. MENA M.A., GARCIA DE YEBENES J. 2008. Glial cells as players in parkinsonism: the 'good', the 'bad' and the 'mysterious' glia. Neuroscientist 14: 544-560.
88. MISRA U.K., TAN C.T., KALITA J. 2008. Viral encephalitis and epilepsy. Epilepsia 49: 13-18.
89. MURAKAMI M., ICHISAKA T., MAEDA M., OSHIRO N., HARA K., EDENHOFER F., KIYAMA H., YONEZAWA K., YAMANAKA S. 2004. mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells. Mol. Cell Biol. 24: 6710-6718.
90. NAGAI M., RE D.B., NAGATA T., CHALAZONITIS A., JESSELL T.M., WICHTERLE H., PRZEDBORSKI S. 2007. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat. Neurosci. 10: 615-622.
91. NAGELE R.G., WEGIEL J., VENKATARAMAN V., IMAKI H., WANG K.C. 2004. Contribution of glial cells to the development of amyloid plaques in Alzheimer's disease. Neurobiol. Aging 25: 663-674.
92. NARDACCI R., ANTINORI A., LAROCCA L.M., ARENA V., AMENDOLA A., PERFETTINI J.L., KROEMER G., PIACENTINI M. 2005. Characterization of cell death pathways in human immunodeficiency virus-associated encephalitis. Am. J. Pathol. 167: 695-704.
93. NORENBERG M.D. 1979. Distribution of glutamine synthetase in the rat central nervous system. J. Histochem. Cytochem. 27: 756-762.
94. NEDERGAARD M., RANSOM B., GOLDMAN S.A. 2003. New roles for astrocytes: redefining the functional architecture of the brain. Trends Neurosci. 26: 523-530.
95. O'CALLAGHAN F.J., SHIELL A.W., OSBORNE J.P., MARTYN C.N. 1998. Prevalence of tuberous sclerosis estimated by capture-recapture analysis. Lancet 351: 1490.
96. OLABARRIA M., NORISTANI H.N., VERKHRATSKY A., RODRIGUEZ J.J. 2010. Concomitant astroglial atrophy and astrogliosis in a triple transgenic animal model of Alzheimer's disease. Glia 58: 831-838.
97. OLABARRIA M., NORISTANI H.N., VERKHRATSKY A., RODRIGUEZ J.J. 2011. Age-dependent decrease in glutamine synthetase expression in the hippocampal astroglia of the triple transgenic Alzheimer's disease mouse model: mechanism for deficient glutamatergic transmission? Mol. Neurodegener. 6: 55.
98. O'SHEA C.C., CHOI S., MCCORMICK F., STOKOE D. 2005. Adenovirus overrides cellular checkpoints for protein translation. Cell Cycle 4: 883-888.
99. PACCALIN M., PAIN-BARC S., PLUCHON C., PAUL C., BESSON M.N., CARRET-REBILLAT A.S, RIOUX-BILAN A., GIL R., HUGON J. 2006. Activated mTOR and PKR kinases in lymphocytes correlate with memory and cognitive decline in Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 22: 320-326.
100. PARPURA V., HENEKA M.T., MONTANA V., OLIET S.H., SCHOUSBOE A., HAYDON P.G., STOUT R.F. Jr., SPRAY D.C., REICHENBACH A., PANNICKE T., PEKNY M., PEKNA M., ZOREC R., VERKHRATSKY A. 2012. Glial cells in (patho) physiology. J. Neurochem. 121: 4-27.
101. PASTOR M.D., GARCÍA-YÉBENES I., FRADEJAS N., PÉREZ-ORTIZ J.M., MORA-LEE S., TRANQUE P., MORO M.A., PENDE M., CALVO S. 2009. mTOR/S6 kinase pathway contributes to astrocyte survival during ischemia. J. Biol. Chem. 284: 22067-22078.
102. PEREA G., NAVARRETE M., ARAQUE A. 2009. Tripartite synapses:astrocytes process and control synaptic information. Trends Neurosci. 32: 421-431.
103. PERYCZ M., SWIECH Ł., MALIK A., JAWORSKI J. 2008. mTor physiology and pathology of the nervous system. Biochim. Biophys. Acta 1784: 116-132.
104. RAVIKUMAR B., VACHER C., BERGER Z., DAVIES J.E., LUO S., OROZ L.G., SCARAVILLI F., EASTON D.F., DUDEN R., O'KANE C.J., RUBINSZTEIN D.C. 2004. Inhibition ofmTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat. Genet. 36: 585-595.
105. REGAZZETTI C., DUMAS K., MARCHAND-BRUSTEY L., PERALDI P., OISTANTI J.F., GIORGETTI-PERALDI S. 2012. Regulated in development and DNA damage responses-1 (REDD1) protein contributes to insulin signaling pathway in adipocytes. PLOS ONE. 7: e52154. DOI: 10.1371/journal. pone.0052154.
106. ROBEL S., BERNINGER B., GOTZ M. 2011. The stem cell potential of glia: lessons from reactive gliosis. Nat. Rev. Neurosci. 12: 88-104.
107. ROSCIC A., BALDO B., CROCHEMORE C., MARCELLIN D., PAGANETTI P. 2011. Induction of autophagy with catalytic mTOR inhibitors reduces huntingtin aggregates in a neuronal cell model. J. Neurochem. 119: 398-407.
108. ROSSI D., BRAMBILLA L., VALORI C.F., RONCORONI C., CRUGNOLA A., YOKOTA T., BREDESEN D.E., VOLTERRA A. 2008. Focal degeneration of astrocytes in amyotrophic lateral sclerosis. Cell Death Differ. 15: 1691-1700.
109. ROSSI D., VOLTERRA A. 2009. Astrocytic dysfunction: Insights on the role in neurodegeneration. Brain Res. Bull. 80: 224-232.
110. ROTHSTEIN J.D., DYKES-HOBERG M., PARDO C.A., BRISTOL L.A., JIN L., KUNCL R.W., KANAI Y., HEDIGER M.A., WANG Y., SCHIELKE J.P., WELTY D.F. 1996. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 16: 675-686.
111. ROWLAND L.P., SHNEIDER N.A. 2001. Amyotrophic lateral sclerosis. N. Engl. J. Med. 344: 1688-1700.
112. SARBASSOV D.D., ALI S.M., KIM D.H., GUERTIN D.A., LATEK R.R., ERDJUMENT-BROMAGE H., TEMPST P., SABATINI D.M. 2004. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptorindependent pathway that regulates the cytoskeleton. Curr. Biol. 14: 1296-1302.
113. SHIGETOMI E., BOWSER D.N., SOFRONIEW M.V., KHAKH B.S. 2008. Two forms of astrocyte calcium excitability have distinct effects on NMDA receptor-mediated slow inward currents in pyramidal neurons. J. Neurosci. 28: 6659-6663.
114. SIMMONS M.L., MURPHY S. 1994. Roles for protein kinases in the induction of nitric oxide synthase in astrocytes. Glia 11: 227-334.
115. SIMPSON J.E., INCE P.G., LACE G., FORTR G., SHAW P.J., MATTHEW F., SAVVA G., BRANE C., WHARTON S.B. 2010. Astrocyte phenotype in relation to Alzheimer-type pathology in the ageing brain. Neurobiol. Aging. 31(4): 578-90
116. SLIPCZUK L., BEKINSCHTEIN P., KATCHE C., CAMMAROTA M., IZQUIERDO I., MEDINA J.H. 2009. BDNF activates mTOR to regulateGluR1 expression required formemory formation. PLoS One. 4: e6007. DOI: 10.1371/journal.pone.0006007.
117. SOFRONIEW M.V. 2005. Reactive astrocytes in neural repair and protection. Neuroscientist 11: 400-407.
118. SOFRONIEW M.V. 2009. Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci. 32: 638-647.
119. SOFRONIEW M.V., VINTERS H.V. 2010. Astrocytes: biology and pathology. Acta Neuropathol. 119: 7-35.
120. SPENCER B., POTKAR R., TREJO M., ROCKENSTEIN E., PATRICK C., GINDI R., ADAME A., WYSS-CORAY T., MASLIAH E. 2009. Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alphasynuclein models of Parkinson's and Lewy body diseases. J. Neurosci. 29: 13578-13588.
121. SPILMAN P., PODLUTSKAYA N., HART M.J., DEBNATH J., GOROSTIZA O., BREDESEN D., RICHARDSON A., STRONG R., GALVAN V. 2010. Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease. PLoS One 5:e9979. DOI: 10.1371/journal.pone.0009979.
122. STAATS K.A., VAN DEN BOSCH L. 2009. Astrocytes in amyotrophic lateral sclerosis: direct effects on motor neuron survival. J. Biol. Phys. 35: 337-346.
123. TAIN L.S. MORTIBOYS H., TAO R.N., ZIVIANI E., BAND-MANN O., WHITWORTH A.J. 2009. Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss. Nat. Neurosci. 12: 1129-1135.
124. TANG S.J., REIS G., KANG H., GINGRAS A.C., SONENBERG N., SCHUMAN E.M. 2002. A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus. Proc. Natl. Acad. Sci. USA 99: 467-472.
125. THAL D.R., SCHULTZ C., DEHGHANI F., YAMAGUCHI H., BRAAK H., BRAAK E. 2000. Amyloid beta-protein (Abeta)-containing astrocytes are located preferentially near N-terminal-truncated Abeta deposits in the human entorhinal cortex. Acta Neuropathol. 100: 608-617.
126. WALTEREIT R., WELZL H., DICHGANS J., LIPP H.P., SCHMIDT W.J., WELLER M. 2006. Enhanced episodic-like memory and kindling epilepsy in a rat model of tuberous sclerosis. J. Neurochem. 96: 407-413.
127. WANG L., GUTMANN D.H., ROOS R.P. 2011. Astrocyte loss of mutant SOD1 delays ALS disease onset and progression in G85R transgenic mice. Hum. Mol. Genet. 20: 286-293.
128. WANG H., ZHANG Q., WEN Q., ZHENG Y., LAZAROVICI P., JIANG H., LIN J., ZHENG W. 2012. Proline-rich Akt substrate of 40kDa (PRAS40): a novel downstream target of PI3k/Akt signaling pathway. Cell Signal. 24: 17-24.
129. WEGGEN S., DIEHLMANN A., BUSLEI R., BEYREUTHER K., BAYER T.A. 1998. Prominent expression of presenilin-1 in senile plaques and reactive astrocytes in Alzheimer's disease brain. Neuroreport 9: 3279-3283.
130. WU X., KIHARA T., AKAIKE A., NIIDOME T., SUGIMOTO H. 2010. PI3K/Akt/mTOR signaling regulates glutamate transporter 1 in astrocytes. Biochem. Biophys. Res. Commun. 393: 514-518.
131. WULLSCHLEGER S., LOEWITH R., HALL M.N. 2006. TOR signaling in growth and metabolism. Cell 124: 471-484.
132. WYSS-CORAY T., LOIKE J.D., BRIONNE T.C., LU E., ANANKOV R., YAN F., SILVERSTEIN S. C., HUSEMANN J. 2003. Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Nat. Med. 9: 453-457.
133. VERKHRATSKY A., SOFRONIEW M.V., MESSING A., DE LAN-EROLLE N.C., REMPE D., RODRÍGUEZ J.J., NEDERGAARD M. 2012. Neurological diseases as primary gliopathies: a reassessment of neurocentrism. ASN Neuro 4: e00082. DOI:10.1042/AN20120007.
134. VICKERS C.A., DICKSON K.S., WYLLIE D.J. 2005. Induction and maintenance of late-phase long-term potentiation in isolated dendrites of rat hippocampal CA1 pyramidal neurones. J. Physiol. 568: 803-813.
135. YAMANAKA K., CHUN S.J., BOILLEE S., FUJIMORI-TONOU N., YAMASHITA H., GUTMANN D.H., TAKAHASHI R., MISAWA H., CLEVELAND D.W. 2008. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat. Neurosci. 11: 251-253.
136. YEH C.Y., VADHWANA B., VERKHRATSKY A., RODRIGUEZ J.J. 2012. Early astrocytic atrophy in the entorhinal cortex of a triple transgenic animal model of Alzheimer's disease. ASN Neuro 3: 271-279.
137. ZENG L.H., XU L., GUTMANN D.H., WONG M. 2008. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann. Neurol. 63: 444-445.